Area of research
Reproductive Medicine · Cancer Research
Research interest
Research interests include Ovarian cancer, Medicine, Serous fluid, Oncology, Ovarian carcinoma, and Biology.
Promoting equitable genetic testing in ovarian cancer: the demonstration of improvement for molecular ovarian cancer testing (DEMO) project
Integrated radiogenomics models predict response to neoadjuvant chemotherapy in high grade serous ovarian cancer
p53 and ovarian carcinoma survival: an Ovarian Tumor Tissue Analysis consortium study
Molecular landscape and functional characterization of centrosome amplification in ovarian cancer
Concurrent RB1 loss and <i>BRCA</i> -deficiency predicts enhanced immunological response and long-term survival in tubo-ovarian high-grade serous carcinoma
Lesion-specific 3D-printed moulds for image-guided tissue multi-sampling of ovarian tumours: A prospective pilot study
Data from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
CCNE1 and survival of patients with tubo‐ovarian high‐grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study
Clonal somatic copy number altered driver events inform drug sensitivity in high-grade serous ovarian cancer
Profiling the immune landscape in mucinous ovarian carcinoma
Clinically Interpretable Radiomics-Based Prediction of Histopathologic Response to Neoadjuvant Chemotherapy in High-Grade Serous Ovarian Carcinoma
Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
Molecular landscape and functional characterization of centrosome amplification in ovarian cancer
Magnetization transfer imaging of ovarian cancer: initial experiences of correlation with tissue cellularity and changes following neoadjuvant chemotherapy
Non-contrast MRI can accurately characterize adnexal masses: a retrospective study
Validated biomarker assays confirm that <scp>ARID1A</scp> loss is confounded with <scp>MMR</scp> deficiency, <scp> CD8 <sup>+</sup> TIL </scp> infiltration, and provides no independent prognostic value in endometriosis‐associated ovarian carcinomas
Diagnostic interpretation of non-contrast qualitative MR imaging features for characterisation of uterine leiomyosarcoma
Integrated radiogenomics models predict response to neoadjuvant chemotherapy in high grade serous ovarian cancer
Prognostic and Immunological Significance of ARID1A Status in Endometriosis-Associated Ovarian Carcinoma
Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE)
Clinical and pathological associations of PTEN expression in ovarian cancer: a multicentre study from the Ovarian Tumour Tissue Analysis Consortium
Ultrasound-guided targeted biopsies of CT-based radiomic tumour habitats: technical development and initial experience in metastatic ovarian cancer
PIK3R1W624R Is an Actionable Mutation in High Grade Serous Ovarian Carcinoma
Kinome capture sequencing of high-grade serous ovarian carcinoma reveals novel mutations in the JAK3 gene
Abstract 1677: Assays of conventional chemotherapeutics and targeted drugs for ovarian cancer using patient derived models
p53 immunohistochemistry is an accurate surrogate for <i>TP53</i> mutational analysis in endometrial carcinoma biopsies
A combination of the immunohistochemical markers CK7 and SATB2 is highly sensitive and specific for distinguishing primary ovarian mucinous tumors from colorectal and appendiceal metastases
Diffusion kurtosis MRI as a predictive biomarker of response to neoadjuvant chemotherapy in high grade serous ovarian cancer
Combination of mTOR inhibition and paclitaxel as a personalised strategy in the context of MYC-amplified high-grade serous ovarian cancer
P112 Activation of PIK3CA in a model of endometriosis may shed light on the pathogenesis of ovarian clear cell adenocarcinoma